Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro

Infusion reactions (IRs) are common immune-mediated side effects in patients treated with a variety of drug products, including, but not limited to, nanotechnology formulations. The mechanism of IRs is not fully understood. One of the best studied mechanisms of IRs to nanomedicines is the complement activation. However, it is largely unknown why some patients develop reactions to nanomedicines while others do not, and why some nanoparticles are more reactogenic than others. One of the theories is that the pre-existing anti-polyethylene glycol (PEG) antibodies initiate the complement activation and IRs in patients. In this study, we investigated this hypothesis in the case of PEGylated liposomal doxorubicin (Doxil), which, when used in a clinical setting, is known to induce IRs; referred to as complement activation-related pseudoallergy (CARPA) in sensitive individuals. We conducted the study in vitro using plasma derived from C57BL/6 mice and twenty human donor volunteers. We used mouse plasma to test a library of well-characterized mouse monoclonal antibodies with different specificity and affinity to PEG as it relates to the complement activation by Doxil. We determined the levels of pre-existing polyclonal antibodies that bind to PEG, methoxy-PEG, and PEGylated liposomes in human plasma, and we also assessed complement activation by Doxil and concentrations of complement inhibitory factors H and I in these human plasma specimens. The affinity, specificity, and other characteristics of the human polyclonal antibodies are not known at this time. Our data demonstrate that under in vitro conditions, some anti-PEG antibodies contribute to the complement activation by Doxil. Such contribution, however, needs to be considered in the context of other factors, including, but not limited to, antibody class, type, clonality, epitope specificity, affinity, and titer. In addition, our data contribute to the knowledge base used to understand and improve nanomedicine safety.

[1]  I. Ayadi,et al.  Molecular basis of complement factor I deficiency in Tunisian atypical haemolytic and uraemic syndrome patients , 2019, Nephrology.

[2]  M. Yaseri,et al.  Association of polymorphisms of complement factor I rs141853578 (G119R) with age-related macular degeneration in Iranian population , 2019, International Ophthalmology.

[3]  W. Boehncke,et al.  Immunogenicity of biologic therapies: causes and consequences , 2018, Expert review of clinical immunology.

[4]  C. Alexiou,et al.  Dextran-coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging: evaluation of size-dependent imaging properties, storage stability and safety , 2018, International journal of nanomedicine.

[5]  J. Szebeni.  Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement? , 2018, Drug discovery today.

[6]  Y. Barenholz,et al.  Anticoagulants Influence the Performance of In Vitro Assays Intended for Characterization of Nanotechnology-Based Formulations , 2017, Molecules.

[7]  E. Groman,et al.  Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population. , 2017, Bioconjugate chemistry.

[8]  A. Cervantes,et al.  Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. Picard,et al.  Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies. , 2017, The journal of allergy and clinical immunology. In practice.

[10]  N Franklin Adkinson,et al.  Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. , 2016, The Journal of allergy and clinical immunology.

[11]  Yu-Cheng Su,et al.  Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. , 2016, Analytical chemistry.

[12]  D. Khan.  Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist. , 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[13]  Scott E. McNeil,et al.  Handbook of Immunological Properties of Engineered Nanomaterials , 2016 .

[14]  Yuqin Wang,et al.  CFI-rs7356506 polymorphisms associated with Vogt-Koyanagi-Harada syndrome , 2016, Molecular vision.

[15]  Marina A Dobrovolskaia,et al.  Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[16]  G. Storm,et al.  Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs. , 2015, Biochemical and biophysical research communications.

[17]  R. Van Ree,et al.  International consensus on allergy immunotherapy. , 2015, The Journal of allergy and clinical immunology.

[18]  S. Lai,et al.  Anti-PEG immunity: emergence, characteristics, and unaddressed questions. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[19]  S. Tomlinson,et al.  Complement: an overview for the clinician. , 2015, Hematology/oncology clinics of North America.

[20]  Y. Bi,et al.  Tag SNPs of CFI contributed to the susceptibility for non-small cell lung cancer in Chinese population , 2015, Tumor Biology.

[21]  P. Reynolds,et al.  Mechanistic Understanding for the Greater Sensitivity of Monkeys to Antisense Oligonucleotide–Mediated Complement Activation Compared with Humans , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[22]  Janos Szebeni,et al.  Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. , 2014, Molecular immunology.

[23]  C. Pang,et al.  CFI-rs7356506 is a genetic protective factor for acute anterior uveitis in Chinese patients , 2014, British Journal of Ophthalmology.

[24]  G. Remuzzi,et al.  Overview of Complement Activation and Regulation , 2013, Seminars in nephrology.

[25]  Á. González-Fernández,et al.  Nanostructures and Allergy , 2013 .

[26]  J. Szebeni,et al.  A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. , 2012, Advanced drug delivery reviews.

[27]  Pascal Richette,et al.  Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents , 2012, Expert opinion on drug delivery.

[28]  M. Joerger.  Prevention and handling of acute allergic and infusion reactions in oncology. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Yaou Duan,et al.  Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids , 2012, Proceedings of the National Academy of Sciences.

[30]  Dan Peer,et al.  Altering the immune response with lipid-based nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[31]  Y. Barenholz,et al.  Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[32]  Yechezkel Barenholz,et al.  Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. , 2011, Advanced drug delivery reviews.

[33]  Hai-Feng Zhang,et al.  Complement factor H Y402H gene polymorphism and coronary heart disease susceptibility: a meta-analysis , 2011, Molecular Biology Reports.

[34]  D. Lawlor,et al.  Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individuals. , 2010, Atherosclerosis.

[35]  M. Gadjeva,et al.  Interaction of human C1q with IgG and IgM: revisited. , 2008, Biochemistry.

[36]  B. Gobel.  Hypersensitivity reactions to biological drugs. , 2007, Seminars in oncology nursing.

[37]  Herbert J Meiselman,et al.  Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients , 2007, Cancer.

[38]  H. Lenz.  Management and preparedness for infusion and hypersensitivity reactions. , 2007, The oncologist.

[39]  Miklós Tóth,et al.  Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles , 2007, Journal of liposome research.

[40]  Johanna M Seddon,et al.  Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration , 2006, Nature Genetics.

[41]  E. Reis,et al.  Clinical Aspects and Molecular Basis of Primary Deficiencies of Complement Component C3 and its Regulatory Proteins Factor I and Factor H , 2006, Scandinavian journal of immunology.

[42]  D. Hepner,et al.  Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. , 2006, The Journal of allergy and clinical immunology.

[43]  C. Alving,et al.  Antibodies to Lipids and Liposomes: Immunology and Safety , 2006, Journal of liposome research.

[44]  R. T. Smith,et al.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Thomas Bieber,et al.  Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. , 2004, The Journal of allergy and clinical immunology.

[46]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[47]  O. Götze,et al.  Complement Activation During Hemorrhagic Shock and Resuscitation in Swine , 2003, Shock.

[48]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  F M Muggia,et al.  ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES , 2002, Journal of liposome research.

[50]  J. Bousquet,et al.  A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. , 2001 .

[51]  C. Alving,et al.  Naturally occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism. , 1999, Immunology today.

[52]  J Szebeni,et al.  Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. , 1999, Circulation.

[53]  S. Meri,et al.  The factor H protein family. , 1999, Immunopharmacology.

[54]  C. Alving,et al.  Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. , 1996, Biochimica et biophysica acta.

[55]  H. Lutz,et al.  Complement amplification revisited. , 2006, Molecular immunology.

[56]  M. Markman,et al.  Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  M. Potter,et al.  Antibodies to cholesterol: biological implications of antibodies to lipids. , 1996, Current topics in microbiology and immunology.

[58]  C. Alving,et al.  Complement activation by liposome-encapsulated hemoglobin in vitro: the role of endotoxin contamination. , 1995, Artificial cells, blood substitutes, and immobilization biotechnology.

[59]  H. Spiegelberg,et al.  Biological role of different antibody classes. , 1989, International archives of allergy and applied immunology.

[60]  E. Åkerblom,et al.  Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. , 1984, International archives of allergy and applied immunology.